Annovis Bio director Hoffman buys 5M shares

Annovis Bio, Inc. director Michael B. Hoffman purchased 5,000,000 common shares and 5,000,000 warrants on November 6, 2026; a footnote states they were acquired for a combined price of $1.00 per share.

Available on EDGAR 11/06/2026 - 04:30 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Annovis Bio, Inc. director Michael B. Hoffman purchased 5,000,000 common shares and 5,000,000 warrants on November 6, 2026; a footnote states they were acquired for a combined price of $1.00 per share. The warrants have a $1.00 exercise price and expire November 6, 2031. After the transactions, Hoffman reported direct holdings of 8,364,883 common shares and 5,000,000 warrants. The 2024 Hoffman Family Trust held 223,357 common shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 10,000,000 shares

Net Buy 2 txns

Insider Hoffman Michael B

Role Director

Bought 10,000,000 shs ($5.00M)

Type	Security	Shares	Price	Value
Purchase	Warrants	5,000,000	$0.00	$0.00
Purchase	Common Stock F1	5,000,000	$1.00	$5.00M
Holding	Common Stock F2	--	--	--

Holdings After Transaction: Warrants — 5,000,000 contracts (Direct); Common Stock — 8,364,883 shares (Direct); Common Stock — 223,357 shares (Indirect, The 2024 Hoffman Family Trust)

Footnotes (2)

1. F1. The 5,000,000 shares of Common Stock and 5,000,000 warrants described in Table I and Table II, respectively, were acquired for a combined price of $1.00 per share.
2. F2. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

Key Figures

Common shares purchased: 5,000,000 shares Warrants acquired: 5,000,000 warrants Combined acquisition price: $1.00 per share +3 more

6 metrics

Common shares purchased 5,000,000 shares November 6, 2026

Warrants acquired 5,000,000 warrants November 6, 2026

Combined acquisition price $1.00 per share For 5,000,000 common shares and 5,000,000 warrants

Warrant exercise price $1.00 per share Warrants expire November 6, 2031

Direct common shares following transaction 8,364,883 shares Reported after the November 6, 2026 transaction

Common shares held by the 2024 Hoffman Family Trust 223,357 shares Reported after the November 6, 2026 transaction

Key Terms

warrants, family trust, voting and investment power

3 terms

warrants financial

"5,000,000 warrants described in Table I and Table II"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

family trust financial

"held in a family trust formed by the reporting person"

voting and investment power regulatory

"has voting and investment power over such shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANVS shares and warrants did Michael B. Hoffman buy?

Michael B. Hoffman purchased 5,000,000 common shares and acquired 5,000,000 warrants on November 6, 2026. A footnote states that the common shares and warrants were acquired for a combined price of $1.00 per share.

What ANVS shares does the 2024 Hoffman Family Trust hold?

The trust held 223,357 common shares. The footnote states that Michael B. Hoffman formed the trust and has voting and investment power over those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Michael B

(Last) (First) (Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2026		P		5,000,000	A	$1(1)	8,364,883	D
Common Stock								223,357	I	The 2024 Hoffman Family Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$1	11/06/2026		P		5,000,000		11/06/2026	11/06/2031	Common Stock	5,000,000	$0	5,000,000	D

Explanation of Responses:

1. The 5,000,000 shares of Common Stock and 5,000,000 warrants described in Table I and Table II, respectively, were acquired for a combined price of $1.00 per share.

2. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

	/s/ Maria Maccecchini Attorney-in-Fact	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)